SAN DIEGO , Oct. 3, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the slide-deck underlying a presentation given yesterday by its Chairman and CEO, Jim Joyce at the EXOSOMES & MICROVESICLES 2012 conference in Orlando, Florida . The presentation was entitled: Extracorporeal clearance of tumor-secreted exosomes as an adjunct to enhance cancer therapy efficacy.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b )

The presentation focused on the potential of the Aethlon Hemopurifier® to be combined with chemo and immunotherapies as a strategy to enhance cancer therapy outcomes. The Hemopurifier®, which is a first-in-class device being advanced in Hepatitis C (HCV) care, has also demonstrated the ability to capture cancer-promoting exosomes secreted by tumors. Tumor-secreted exosomes have emerged to become a potentially vital therapeutic target in cancer as researchers have reported these microvesicular particles promote tumor progression by inducing programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. Researchers have also reported that exosomes seed the spread of metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.

The slide-deck of the presentation can be accessed on the Aethlon Medical website at: http://aethlonmedical.investorroom.com/index.php?s=19